"The favorable safety and PK data reported today provide further
evidence for the large potential therapeutic window for NEUGENE
antisense drugs. This is in sharp contrast to previous antisense
failures by other companies with other antisense chemistries, which
have been primarily due to dose-limiting toxicity"

<tedw2@earthlink.net> wrote in message
news:1140625215.608708.118200@g47g2000cwa.googlegroups.com...

Quote:

"The favorable safety and PK data reported today provide further
evidence for the large potential therapeutic window for NEUGENE
antisense drugs. This is in sharp contrast to previous antisense
failures by other companies with other antisense chemistries, which
have been primarily due to dose-limiting toxicity"
http://www.pharmaweek.com/Business_and_Markets/Hep%20C%20Drugs.asp
Anybody understand how these neugene antisense drugs work?

Hell, man, I don't understand the first paragraph!

Seriously, it sounds like a stock promo.
I'd try googling "neugene" to find something objective from a medical
journal.
I've cross-posted this to alt.support.hepatitis-c; lots of well-informed
folks over there.

They may be well informed but it doesnt seem like most know anything
about this.

True, and if you knew about this drug before yesterday, you were holding out
on us ;-)

Drugs still in Phase 1 trials are generally a *minimum* of 5 years from final
regulatory approval, and that's a distant horizon for someone with significant
fibrosis or other HCV manifestations. There are lots of drugs in Phase 2 and
some in Phase 3 that make more "noise" here simply because they're closer to
becoming "real".

Anyway....What's really cool about this particular drug is the conceptual
basis is as elegant as it is novel, yet one can readily understand how it
works. By contrast, consider that nobody really understands how Ribavirin
works, yet *that* is approved for use ;-)

I didn't see anything relating to SVR in the animal studies - just that
it suppressed the virus without serious side-effects.

It sounds like you're on the bleeding edge of research here. The worst
case would be that the virus comes back stronger after the drug is
discontinued (this is a problem with one of the Hep B drugs), the
probable case is that it will suppress the virus during the 14 days with
a return to previous levels after it's discontinued, a better case is
that the return is slow, and absolute best is that it's a 14-day
wonder-drug cure.

They may be well informed but it doesnt seem like most know anything
about this.

True, and if you knew about this drug before yesterday, you were holding out
on us ;-)

Drugs still in Phase 1 trials are generally a *minimum* of 5 years from final
regulatory approval, and that's a distant horizon for someone with significant
fibrosis or other HCV manifestations. There are lots of drugs in Phase 2 and
some in Phase 3 that make more "noise" here simply because they're closer to
becoming "real".

Anyway....What's really cool about this particular drug is the conceptual
basis is as elegant as it is novel, yet one can readily understand how it
works. By contrast, consider that nobody really understands how Ribavirin
works, yet *that* is approved for use ;-)